| 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：合富中国 | | --- | --- | | 保荐代表人姓名：冯超、陈邦羽 | 被保荐公司代码：603122 | 经中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公司 首次公开发行股票的批复》（证监许可[2021]4074 号）批复，合富（中国）医疗 科技股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股 票 99,513,200 股，每股面值人民币 1 元，每股发行价格人民币 4.19 元，募集资 金总额为人民币 416,960,308.00 元，扣除发行费用后，实际募集资金净额为人民 币 359,690,993.41 元。本次发行证券已于 2022 年 2 月 16 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续 督导保荐机构，持续督导期间为 2022 年 2 月 16 日至 2024 年 12 月 31 日。 在 2022 年 2 月 16 日至 2024 年 12 月 31 日持续督导期内（以下简称"本持 续督导期间"），保荐机构及保荐代表人按照《证券发行上市 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥1.09 billion, a decrease of 14.62% compared to ¥1.28 billion in 2022[24]. - Net profit attributable to shareholders decreased by 42.96% to approximately ¥47.19 million in 2023 from ¥82.72 million in 2022[24]. - Basic earnings per share fell by 45.45% to ¥0.12 in 2023, down from ¥0.22 in 2022[24]. - The weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[24]. - The total revenue for the year reached ¥1,092,272,353.17, representing a year-on-year increase of 20.70%[59]. - The operating income from the medical product circulation segment decreased significantly by 72.13% year-on-year, amounting to ¥57,426,153.35[59]. - The gross profit margin for the medical product circulation segment was reported at 26.55%, down by 12.23 percentage points compared to the previous year[59]. - The company reported a total revenue of 1,092,602,026.63 RMB for the reporting period, a decrease of 14.62% compared to the previous year[54]. - The net profit attributable to shareholders was 47,186,900 RMB, reflecting a significant decline of 42.96% year-over-year[54]. Cash Flow and Assets - The net cash flow from operating activities improved to approximately ¥11.28 million in 2023, compared to a negative cash flow of ¥30.37 million in 2022[24]. - The total assets at the end of 2023 were approximately ¥1.46 billion, a decrease of 6.26% from ¥1.56 billion at the end of 2022[24]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥1.17 billion, a slight decrease of 0.93% from ¥1.18 billion at the end of 2022[24]. - The total operating costs for the year were ¥866,158,543.42, a reduction from ¥1,021,774,257.93 in the previous year[63]. - The net cash flow from operating activities was ¥11,281,136.90, a significant improvement from a negative cash flow of ¥30,366,164.41 in the same period last year[75]. Strategic Initiatives and Future Outlook - The company aims to achieve approximately CNY 1.248 billion in revenue and a net profit of around CNY 79 million for the year 2024[96]. - The company plans to enhance customer loyalty by providing differentiated empowerment services and expanding its customer base[96]. - The company will focus on expanding its marketing network nationwide, particularly in regions where it has not yet established operations[92]. - The company is committed to optimizing and upgrading its centralized procurement services for in vitro diagnostic reagents and consumables[91]. - The company plans to enhance its digital marketing efforts, allocating an additional 2 million to boost online presence and engagement[113]. Corporate Governance and Compliance - The company has established a complete independent financial accounting system and internal control measures, ensuring financial independence from the controlling shareholder[106]. - The company has received a standard unqualified opinion on the effectiveness of its internal control from KPMG Huazhen, indicating robust internal control practices[146]. - The company has not experienced any major legal violations or penalties during the reporting period[105]. - The company has established an independent organizational structure, ensuring that the shareholders' meeting, board of directors, and supervisory board operate independently without interference from controlling shareholders[107]. - The company has no actual controller, leading to potential instability in governance and operational decision-making risks[98]. Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, with total donations amounting to ¥90.13 million, including ¥52.87 million in cash and ¥37.26 million in material contributions[155]. - The company committed to supporting national poverty alleviation and rural revitalization efforts, donating ¥60,000 to improve educational opportunities for underprivileged youth[156]. - The company donated medical clinical testing equipment and reagents to 8 hospitals in Guanghe County, benefiting approximately 200-500 patients[157]. - The company aims to continue leveraging its resources to support social welfare and rural revitalization as part of its corporate social responsibility[157]. Research and Development - Research and development expenses increased by 13.70% to 3,182,530.27 RMB, indicating a focus on innovation and new product development[55]. - The company is investing heavily in R&D for new technologies, with a budget allocation of 10 million for the upcoming year[113]. - The company has 9 R&D personnel, accounting for 3.75% of the total workforce, with 1 holding a master's degree and 8 holding bachelor's degrees[71]. Shareholder Matters and Dividends - The board proposed a cash dividend of CNY 0.60 per share, totaling approximately CNY 23.88 million, pending shareholder approval[6]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit will be distributed as cash dividends if conditions are met[135]. - The total dividend amount (including tax) is ¥23,883,157.98, which also represents 50.61% of the consolidated net profit attributable to ordinary shareholders[142]. - The company’s profit distribution plan requires a two-thirds majority approval from shareholders at the general meeting[137].

Financial Performance - Revenue for the reporting period was RMB 1,092.60 million, a decrease of 14.62% year-on-year[8] - Net profit attributable to shareholders of the listed company was RMB 47.19 million, a decrease of 42.96% year-on-year[8] - Revenue for the third quarter was RMB 267.93 million, with a net profit attributable to shareholders of RMB 13.15 million[6] - Total assets decreased by 6.26% to 1,461,406,215.62 in 2023 compared to 1,559,065,109.86 in 2022[22] - Revenue declined by 14.62% to 1,092,602,026.63 in 2023 from 1,279,666,218.81 in 2022[22] - Net profit attributable to shareholders dropped by 42.96% to 47,186,921.09 in 2023 from 82,719,667.82 in 2022[22] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 38.18% to 46,919,175.91 in 2023 from 75,895,588.47 in 2022[22] - Weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[22] - Basic earnings per share fell by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] - Diluted earnings per share also decreased by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] Cash Flow and Shareholder Information - Operating cash flow for the reporting period was RMB 11.28 million, an increase of RMB 41.65 million compared to the same period last year[8] - The company's operating cash flow turned positive in the second quarter and continued to be positive in the third quarter[1] - The number of ordinary shareholders at the end of the reporting period was 35,311, a decrease from 36,341 at the end of the previous month[3] - The largest shareholder, Hefu (Hong Kong) Holdings Limited, holds 55.00% of the company's shares[3] - Operating cash flow turned positive to 11,281,136.90 in 2023 from -30,366,164.41 in 2022[22] Strategic Adjustments and Business Focus - The company has reduced non-terminal medical product distribution business to focus on strategic adjustments and risk control[1] - The company has established a talent team to promote empowerment projects and increase customer stickiness[1] - The company is focusing on technological innovation and service capabilities to meet the increasing demands of the market[12][13] - The company signed medium and long-term contracts with medical institutions, covering 4 new provinces and adding over 20 new terminal customers[14] - The company's medical product distribution business focuses on sales and maintenance of radiotherapy equipment, as well as sales of immunodiagnostic and biochemical diagnostic equipment[14] - The company's hospital empowerment platform includes services such as key specialty co-construction, group hospital strategic planning, and clinical innovation research collaboration[21] - The company's integrated business platform provides value-added services to medical institutions, including unified procurement, distribution, and inventory management of reagents and consumables[14] Market and Industry Trends - The domestic in vitro diagnostics market has exceeded RMB 100 billion and is expected to continue growing due to increased health awareness and aging population[18] Technological Innovation and Product Development - The company launched a decision analysis integrated platform, with over 10 medical institutions deciding to adopt it by year-end[21] - The company's subsidiary, Heyi Information, will localize production of the surgical audio-visual imaging chain integration platform "Metaway" in mainland China[21] - The company collaborated with Zhejiang University's Computer Innovation Technology Institute to develop a clinical diagnostic assistance system using AI and big data analysis[21] Cross-Strait Collaboration and Resource Sharing - The company facilitated cross-strait medical resource sharing, assisting mainland medical institutions in training in Taiwan and introducing Taiwanese experts to mainland hospitals[14] Dividend Proposal - The company proposed a cash dividend of RMB 0.60 per 10 shares, totaling RMB 23,883,157.98 (tax included), pending shareholder approval[16]

合富（中国）医疗科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603122 证券简称：合富中国 公告编号：临 2024-013 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 4 月 29 日 14 点 30 分 召开地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 重要内容提示： 一、召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 (二) 股东大会召集人：董事会 股东大会召开日期：2024年4月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 4 月 29 日 至 2024 年 4 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

海通证券股份有限公司 关于合富（中国）医疗科技股份有限公司 2024年度预计担保额度的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为合富（中 国）医疗科技股份有限公司（以下简称"合富中国"或"公司"）首次公开发行股票 并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 监管指引第8号——上市公司资金往来、对外担保的监管要求》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第11号——持续督导》 《上海证券交易所上市公司自律监管指引第1号——规范运作》等有关规定，对 公司2024年度预计担保额度事项进行了核查，具体情况如下： 一、担保情况概述 二、被担保人的基本情况 | 被担保人 | 合益信息科技（上海）有限公司 成立时间 | 2005 年 | | | 10 月 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 1 | 11 日 | | | | | | | | | 注册资本 | 3,423 万人民币 法定代表人 王琼芝 | | | | | | | | | 注册 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-013 合富（中国）医疗科技股份有限公司 关于 2024 年度预计担保额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：合富（中国）医疗科技股份有限公司（以下简称"公 司"、"本公司"）全资子公司合益信息科技（上海）有限公司（以下简称"合益 信息"）、上海合康医院管理咨询有限公司（以下简称"合康医管"）、合康生物 技术开发（上海）有限公司（以下简称"合康生物"）、合富（上海）医疗技术 有限公司（以下简称"合富上海"）、合玺（香港）控股有限公司（ROYAL SEAL HOLDING CO.,LIMITED）（以下简称"合玺香港"） 已实际为其提供的担保余额：截至目前公司为上述 5 家全资子公司累计 担保额度为 0 万元。 公司为全资子公司提供的担保额度及被担保方的基本情况如下： （二）履行的内部决策程序 公司于 2024 年 3 月 22 日召开第二届董事会第九次会议，审议通过了《关 于公司 2024 年度对外担保额度计划 ...

合富（中国）医疗科技股份有限公司 自 2023 年 1 月 1 日 至 2023 年 12 月 31 日止年度财务报表 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 近外韩是古外柴共被口出 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码 : 100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2401425 号 合富 (中国) 医疗科技股份有限公司全体股东: 一、审计意见 我们审计了后附的合富（中国）医疗科技股份有限公司（以下简称"合富中国"）财务报 表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润 表、合并及母公司现金流量表、合并及 ...

合富 (中国) 医疗科技股份有限公司 募集资金 2023 年度存放与实际使用情况专项报告的鉴证报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 对合富 (中国) 医疗科技股份有限公司 募集资金 2023 年度存放与实际使用情况专项报告的鉴证报告 毕马威华振专字第 2400115 号 合富 (中国) 医疗科技股份有限公司董事会: 我们接受委托，对后附的合富 (中国) 医疗科技股份有限公司 (以下简称"贵公司") 募集 资金 2023 年度存放与实际使用情况的专项报告(以下简称"专项报告") ...

合富（中国）医疗科技股份有限公司 2023 年度独立董事述职报告 本人周露露，作为合富（中国）医疗科技股份有限公司（以下简称 "公司"） 的独立董事，2023年度，严格按照《公司法》、《上市公司治理准则》、《上海 证券交易所上市公司自律监管指引第1号——规范运作》、《上市公司独立董事 管理办法》等法律法规及《公司章程》、《独立董事工作制度》的相关规定，履 行独立董事职责，现就2023年度履职情况作如下述职报告： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 周露露：女，中国台湾籍，有境外永久居留权，1957年7月出生，硕士学历。 1983年至1986年担任希格耐科技公司会计；1986年至1994年担任安达信会计师事 务所税务部税务经理；1994年至2019年担任中国台湾积体电路股份有限公司会计 处处长；2019年11月至今担任公司独立董事。 （二）是否存在影响独立性的情况说明 本人作为独立董事具备独立性，不属于下列情形： 1、在上市公司或者其附属企业任职的人员及其配偶、父母、子女、主要社 会关系； 2、直接或者间接持有上市公司已发行股份百分之一以上或者是上市公司前 十名股东中的自然人股东及其配 ...

合富（中国）医疗科技股份有限公司 关于 2023 年度会计师事务所的履职情况评估报告 机构名称：毕马威华振会计师事务所（特殊普通合伙） 成立日期：1992 年 8 月 18 日在北京成立（于 2012 年 7 月 5 日获财政部批 准转制为特殊普通合伙的合伙制企业） 组织形式：特殊普通合伙 注册地址：北京市东城区东长安街 1 号东方广场东 2 座办公楼 8 层 首席合伙人：邹俊 截至 2023 年 12 月 31 日合伙人数量：234 人。 截至 2023 年 12 月 31 日注册会计师人数：1,121 人，其中签署过证券服务 业务审计报告的注册会计师超过 260 人。 根据《国有企业、上市公司选聘会计师事务所管理办法》的要求，合富 （中国）医疗科技股份有限公司（以下简称"公司"或"本公司"）对 2023 年 度的财务报表及内部控制审计机构毕马威华振会计师事务所（特殊普通合伙） （以下简称"毕马威华振"）的履职情况进行评估。经评估，公司认为毕马威 华振资质等方面合规有效，履职保持独立性，勤勉尽责，公允表达意见，具体 情况如下： 一、资质条件 毕马威华振 2022 年经审计的业务收入总额超过人民币 41 亿元 ...